Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥ 3)—The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).

Authors

Michael Friedlander

Prince of Wales Cancer Centre, Randwick, Australia

Michael Friedlander , Martin R. Stockler , Rachel O'Connell , Florence Joly , Anne Lanceley , Felix Hilpert , Aikou Okamoto , Eriko Aotani , Sandro Pignata , Paul P. Donnellan , Amit M. Oza , Elisabeth Avall-Lundqvist , Jonathan S. Berek , Katrin Marie Sjoquist , Kim Gillies , Phyllis Butow , Madeleine Trudy King

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient reported outcomes (PRO) on chemotherapy randomization.

First Author: Karen Basen-Engquist

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).

First Author: Elizabeth M. Swisher

insert_chart_outlined

Poster

2018 ASCO Quality Care Symposium

bookmark_border

Assessment of scheduled pharmacy follow-up for patients receiving oral chemotherapy.

First Author: Emily R. Mackler

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).

First Author: Michael Friedlander